Business Context and Reporting Period
This Form 8-K Current Report was filed by Protalix Biotherapeutics, Inc. on February 13, 2008, covering events that occurred on February 7, 2008. The filing primarily addresses corporate governance changes, specifically the appointment of a new director and significant adjustments to executive compensation.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The financial data presented is limited to specific compensation figures for executive officers and the terms of stock option grants.
| Executive Officer | Amended Monthly Salary (NIS) | 2007 Annual Bonus | Stock Option Grant | Option Exercise Price |
|---|---|---|---|---|
| David Aviezer, Ph.D. (CEO) | 136,000 (~$37,559) | 920,000 NIS (~$256,131) | 600,000 shares | $5.00 |
| Yoseph Shaaltiel, Ph.D. (EVP R&D) | 60,500 (~$16,727) | $50,000 | 263,728 shares | $5.00 |
| Einat Brill Almon, Ph.D. (VP Product Dev) | 55,000 (~$15,206) | $50,000 | 311,272 shares | $5.00 |
| Yossi Maimon, CPA (CFO) | 55,000 (~$15,206) | 297,000 NIS (~$82,061) | 175,000 shares | $5.00 |
Additionally, Professor Roger D. Kornberg was granted an option to purchase 50,000 shares at an exercise price of $3.02 per share.
Material Changes
- Board Appointment: Professor Roger D. Kornberg, a Nobel Prize laureate in Chemistry, was appointed to the Board of Directors to serve until the next annual meeting.
- Executive Compensation Increases: Base salaries for four executive officers were increased, effective retroactively to January 1, 2008.
- Bonus Grants: Annual bonuses for the fiscal year 2007 were granted to the executive officers, payable in cash.
- Stock Option Grants: New stock options were granted to the executive officers under the 2006 Stock Incentive Plan.
- Option Amendment: Outstanding options held by Dr. Aviezer, Dr. Brill Almon, and Mr. Maimon were amended to include accelerated vesting upon a change in control.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, future outlook, or management commentary regarding business operations. The primary risk factor disclosed relates to the dilution of shareholder equity resulting from the new stock option grants and the potential for accelerated vesting of options upon a change in control.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2006 Stock Incentive Plan to assess remaining capacity for future grants.
- Confirm the current market price of Protalix common stock relative to the $5.00 exercise price of the executive options and the $3.02 price for the director's options.
- Review the Company's cash position to ensure sufficient liquidity exists to pay the approximately $468,000 in cash bonuses awarded to executives.
- Examine the specific vesting schedules for the new executive options to understand the timeline for potential dilution.